Summary & Overview
HCPCS Level II J9370: Vincristine Sulfate, 1 mg
HCPCS Level II code J9370 denotes vincristine sulfate, 1 mg, an intravenous chemotherapeutic agent commonly used in oncology regimens. Nationally, accurate billing for single-drug units like J9370 is important for clinical documentation, payer adjudication, and cost tracking in cancer care. The code is used across hospital outpatient infusion centers, physician offices, and specialty oncology clinics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for vincristine administration, payer coverage considerations, common billing modifiers (listed elsewhere in the publication), and benchmarking items relevant to drug-unit billing. The publication also highlights policy and coding considerations that affect reimbursement, such as unit dosing and billing conventions for single-drug HCPCS codes.
This resource is intended to help coding professionals, revenue cycle staff, and policy analysts understand the role of J9370 in oncology billing workflows, typical sites of service, and the categories of information to review when processing claims. Data not available in the input are noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J9370 represents vincristine sulfate, 1 mg, an antineoplastic (chemotherapy) agent supplied for intravenous administration. This code is used to bill for the drug product itself when administered as part of cancer treatment regimens.
-
Service type: Injectable chemotherapy drug
-
Typical site of service: Hospital outpatient infusion centers, physician office infusion suites, and cancer clinics
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55-year-old female with newly diagnosed diffuse large B-cell lymphoma scheduled to receive combination chemotherapy including vincristine. The patient presents to an outpatient oncology infusion center for administration of intravenous chemotherapy. After verification of identity, diagnosis, consent, and review of labs (including complete blood count and liver function tests), the oncology nurse and pharmacist prepare vincristine sulfate dosed per body surface area. The drug is supplied and billed as J9370 per milligram and is administered via peripheral IV or central venous access (for example, implanted port) as part of a multiagent regimen. Documentation includes diagnosis linking to the chemotherapy order, lot number and amount of drug dispensed, route of administration, site of service (outpatient infusion center or hospital outpatient department), and any applicable modifier (for example JW for discarded drug or 59 if distinct procedural service is reported). Monitoring for neuropathy, constipation, and extravasation is performed during and after infusion. Billing follows verification of appropriate diagnosis codes, clinician order, and infusion administration record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |